The Future of Clinical Research with Digital Biomarkers

Clinical vs Digital Biomarkers

Biomarkers, concise indicators of biological processes or conditions, are typically acquired through traditional clinical assessments during in-person healthcare consultations. Examples include blood pressure readings, serum cholesterol analyses, and blood sugar measurements.

Digital biomarkers represent a modern data collection and measurement approach. They are objective, quantifiable physiological and behavioral data obtained through digital devices like smartphones and wearable fitness trackers. They offer a continuous and real-time picture of a patient’s health, transforming clinical research.

Also Read: What Patients Need to Know About the Role of Digital Twins in Personal Health Management

How Digital Biomarkers Help in Clinical Research

Accurate Clinical Trials:

Reduce Clinical Trial Cost: Digital biomarkers increase precision and reduce the cost of clinical trials, speeding up the time to market medicines and improving the return on investment for pharmaceutical companies. It enables remote patient monitoring, facilitating decentralized or hybrid clinical trials. This results in lower costs and quicker drug development timelines.

Real-Time Data Collection: Digital tools passively collect data from connected devices, minimizing incomplete data, a frequent hurdle in traditional trials. This real-time data allows researchers to address any issues promptly.

Also Read: Fine-Tuning AI as a Catalyst for Medical Innovation

Better Disease Management:

Better Disease Predictions and Management: Digital biomarkers are crucial in monitoring and managing disease outbreaks at national and individual levels. For instance, during the COVID-19 pandemic, digital biomarkers capable of monitoring temperature, breathing patterns, and voice characteristics aid in infection detection and management at healthcare facilities. Additionally, the aggregated data aids policymakers in understanding outbreak trends and patterns, enabling better predictions and management strategies.

Easy Disease Diagnosis: Digital biomarkers can add value to diagnostics through early disease detection and reducing misdiagnosis. Early disease detection means better targeting of additional patients for early diagnosis and adding value through early treatment initiation.

Personalized Treatment: Digital biomarkers, being inherently personalized, enable clinicians to identify changes in a patient’s health and treatment adherence. Predictive insights derived from these biomarkers aid in understanding a patient’s disease trajectory and improving their quality of life through tailored interventions.

Also Read: Top 3 Use Cases of AI From a Healthcare Technology Leader

Risk Evaluation and Cost Reduction:

Early Risk Management: Continuous monitoring of health conditions using digital biomarkers enables clinicians to assess patient risk levels, facilitating early diagnosis and treatment of comorbidities. For example, monitoring blood glucose, weight, activity, and diet in diabetic patients allows for early risk management and personalized treatment adjustments.

Reduce Healthcare Costs: Digital biomarkers continuously monitor an individual’s physiological parameters. Analysis of these measurements can provide early signs of health issues – and the ability to deliver proactive interventions and preventive measures. Early detection typically leads to more accessible and less expensive treatment. Tailored treatments based on biomarker data optimize patient outcomes and minimize hospitalization costs and time spent in healthcare facilities.

How AI can help in Clinical Research and Drug Development

The COVID-19 pandemic has accelerated the adoption of AI and big data analytics in the pharmaceutical industry. Over the past few years, the availability of extensive datasets and technological advancements have fueled interest in AI for drug discovery.

This powerful technology mimics human intelligence to tackle complex challenges in the new drug creation process. By adopting AI solutions, researchers can streamline the clinical trial process, eliminating potential roadblocks and significantly reducing trial times. This translates to faster and more efficient drug development, ultimately leading to life-saving medications reaching patients sooner.

• Life science industry players are increasingly interested in using these advanced AI solutions in drug development.
• In the pharmaceutical industry, it helps find new chemicals, find treatment targets, and make more personalized medicines.

Ultimately, AI-powered drug development offers a promising avenue for uncovering new treatments and alleviating the burden of chronic diseases.

Digital Biomarkers – The Future of Precision Medicine

Digital biomarkers hold immense potential for transforming clinical research. Their ability to provide real-time, objective data offers a more comprehensive understanding of patient health and treatment outcomes. As technology advances and regulatory frameworks evolve, we expect to see greater integration of digital biomarkers in clinical research.

Big data and related analytics using digital biomarker devices drive hidden insight, connections, and touchpoints. The data generated using digital devices empowered consumer and data collection, active or passive, giving strategic direction to drug development companies in their clinical research.

The promise of AI in drug development extends far beyond streamlining processes. Researchers can unlock a deeper understanding of diseases, leading to the discovery of entirely new drug classes and more targeted therapies. This will result in a brighter future for patients battling chronic illnesses, offering them not just symptom management but potentially curative solutions. This powerful synergy between human ingenuity and artificial intelligence is key to unlocking a new era of medical breakthroughs.